Alnylam Pharmaceuticals (BSP:A1LN34) EV-to-EBIT : -56.09 (As of May. 01, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Alnylam Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alnylam Pharmaceuticals's Enterprise Value is R$87,278 Mil. Alnylam Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was R$-1,556 Mil. Therefore, Alnylam Pharmaceuticals's EV-to-EBIT for today is -56.09.

The historical rank and industry rank for Alnylam Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

BSP:A1LN34' s EV-to-EBIT Range Over the Past 10 Years
Min: -74.16 Med: -22.24 Max: -5.8
Current: -54.56

During the past 13 years, the highest EV-to-EBIT of Alnylam Pharmaceuticals was -5.80. The lowest was -74.16. And the median was -22.24.

BSP:A1LN34's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.725 vs BSP:A1LN34: -54.56

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alnylam Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was R$106,778 Mil. Alnylam Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was R$-1,556 Mil. Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.46%.

Alnylam Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Alnylam Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals EV-to-EBIT Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-13.20

-17.87

-26.71

-29.43

-73.47

Alnylam Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-29.43	-26.31	-24.72	-55.14	-73.47

Competitive Comparison of Alnylam Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Alnylam Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alnylam Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's EV-to-EBIT falls into.

Alnylam Pharmaceuticals EV-to-EBIT Calculation

Alnylam Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	87278.054	/	-1556.15
	=	-56.09

Alnylam Pharmaceuticals's current Enterprise Value is R$87,278 Mil.
Alnylam Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1,556 Mil.

Alnylam Pharmaceuticals (BSP:A1LN34) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-1556.15	/	106777.693
	=	-1.46 %

Alnylam Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was R$106,778 Mil.
Alnylam Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1,556 Mil.

Alnylam Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals (BSP:A1LN34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (BSP:A1LN34) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals (BSP:A1LN34) Headlines

No Headlines